17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The role of the unfolded protein response in cancer progression: From oncogenesis to chemoresistance : Unfolded Protein Response in Cancer Progression

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumour cells endure both oncogenic and environmental stresses during cancer progression. Transformed cells must meet increased demands for protein and lipid production needed for rapid proliferation and must adapt to exist in an oxygen- and nutrient-deprived environment. To overcome such challenges, cancer cells exploit intrinsic adaptive mechanisms such as the unfolded protein response (UPR). The UPR is a pro-survival mechanism triggered by accumulation of unfolded or misfolded proteins in the endoplasmic reticulum (ER), a condition referred to as ER stress. IRE1, PERK and ATF6 are three ER anchored transmembrane receptors. Upon induction of ER stress, they signal in a coordinated fashion to re-establish ER homoeostasis, thus aiding cell survival. Over the past decade, evidence has emerged supporting a role for the UPR in the establishment and progression of several cancers, including breast cancer, prostate cancer and glioblastoma multiforme. This review discusses our current knowledge of the UPR during oncogenesis, tumour growth, metastasis and chemoresistance.

          Related collections

          Author and article information

          Journal
          Biology of the Cell
          Biol. Cell
          Wiley
          02484900
          January 2019
          January 2019
          October 29 2018
          : 111
          : 1
          : 1-17
          Affiliations
          [1 ]School of Natural Sciences; NUI Galway; Ireland
          [2 ]Apoptosis Research Centre; NUI Galway; Ireland
          [3 ]Université Claude Bernard Lyon 1; INSERM 1052; CNRS 5286; Centre Léon Bérard; Cancer Research Center of Lyon; Lyon 69008 France
          Article
          10.1111/boc.201800050
          30302777
          dad5810c-ba82-4a22-b50d-fcabf0263509
          © 2018

          http://doi.wiley.com/10.1002/tdm_license_1.1

          http://creativecommons.org/licenses/by-nc/4.0/

          History

          Comments

          Comment on this article